CBD inhibited colorectal cancer cell proliferation by targeting the HIF-1alpha/LDHA glycolysis pathway, cutting off the abnormal glucose metabolism that fuels tumor growth.
Cancer researchers, oncologists following cannabinoid research, and anyone interested in novel approaches to targeting cancer metabolism.
What the researchers found
CBD downregulated HIF-1alpha, LDHA, and GLUT1, reducing ATP production, glucose uptake, and lactate levels in colon cancer cells. When combined with glycolysis inhibitor 2-DG, the anti-tumor effects were enhanced, confirming pathway dependency.
Why it matters
Colorectal cancer cells reprogram their metabolism to grow faster (the Warburg effect). CBD's ability to disrupt this metabolic reprogramming represents a novel mechanism beyond simple cell killing, potentially making tumors more vulnerable to other treatments.
The numbers in context
CBD reduced tumor cell proportions in single-cell analysis. Dose-dependent reductions in ATP, glucose uptake, and lactate. HIF-1alpha agonist DMOG partially reversed effects. PTGS2 identified as central target.
How the study worked
Multi-omics approach including single-cell transcriptomics, network pharmacology, proteomics, in vitro functional assays, metabolic assays, rescue experiments, and synergy testing with glycolysis inhibitor 2-DG.
What this study cannot tell us
In vitro study primarily — in vivo validation is limited. Achievable tissue concentrations of CBD may differ from experimental doses. Single cancer type studied.
How to read the evidence
Comprehensive multi-omics approach with pathway validation, but primarily in vitro with limited in vivo confirmation.
When this study was published
Recent study applying cutting-edge multi-omics methods to understand CBD's anticancer mechanisms.
The bigger picture
Cancer metabolism is a growing therapeutic target. CBD's ability to attack cancer's energy supply through a specific molecular pathway adds to its multi-mechanism anticancer profile and could complement existing chemotherapy approaches.
Questions still open
- Would CBD enhance standard colorectal cancer chemotherapy by disrupting metabolic resistance? Could metabolic biomarkers predict which patients might respond to CBD?
Common questions
Can CBD treat colon cancer?
What is the Warburg effect?
Read the original research
Cannabidiol Reprograms Glucose Metabolism in Colorectal Adenocarcinoma by Targeting HIF-1α/LDHA Pathway.
The American journal of Chinese medicine, 53(8), 2561-2578
Citation
Zhang, Yuzhe; Gao, Zhengtao; Li, Yanke; Zhang, Lulu; Yan, Lirong; Liu, Aoran; Li, Fang; Peng, Xiaoli; Li, Ruipeng; Wang, Yan; Wu, Lina; Zhang, Ye. (2025). Cannabidiol Reprograms Glucose Metabolism in Colorectal Adenocarcinoma by Targeting HIF-1α/LDHA Pathway.. The American journal of Chinese medicine, 53(8), 2561-2578. https://doi.org/10.1142/S0192415X25500958
Explore the wider topic
- CBD Oil Quality Guide: How to Avoid Snake Oil
- Anxiety After Quitting Weed: When to Consider Medication
- Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
- Cannabis for Chronic Pain: What the Research Actually Supports
- Cannabis and Epilepsy: The Epidiolex Story and What It Means
- Does CBD Actually Work for Anxiety? What the Evidence Shows
- Does CBD Help with Weed Withdrawal? What Studies Show
- CBD vs THC: The Differences That Actually Matter
- The Proven Medical Benefits of Cannabis: What Research Supports
- Quitting Weed Before Surgery
- Weed and Medications: What Changes When You Quit
- Quitting Weed During Pregnancy: What You Need to Know
- Quitting Weed While Pregnant: What You Need to Know
- Cannabis and Older Adults: Risks Seniors Should Know
- Cannabis and Breastfeeding: THC in Breast Milk